Heron Therapeutics, Inc.HRTXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +4.38% | +19.13% | +12.21% | +3.26% | +16.47% |
| Gross Profit Growth | +76.56% | +25.48% | +16.09% | +7.20% | -2.24% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +5.41% | +1.91% | +1.52% | +1.13% | +11.46% |
| Weighted Average Shares Diluted Growth | +5.41% | +1.91% | +1.52% | +1.13% | +11.46% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -579.84% | +0.00% | +0.00% | -60.52% |
| Free Cash Flow Growth | +0.00% | -663.17% | +0.00% | +0.00% | -54.73% |
| Receivables Growth | +5.09% | +31.17% | +20.54% | +8.44% | +20.90% |
| Inventory Growth | +9.39% | +26.24% | +34.04% | +70.22% | +52.39% |
| Asset Growth | -3.67% | +4.78% | +8.20% | +6.40% | +12.76% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -0.97% | -1.04% | -1.07% | -1.10% | -21.21% |
| R&D Expense Growth | -67.07% | -70.98% | -50.54% | -33.80% | -22.28% |
| SG&A Expenses Growth | -5.09% | -1.76% | -5.31% | -5.35% | +15.32% |